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Standardized Endpoint Definitions for
Transcatheter Aortic Valve Implantation Clinical Trials
A Consensus Report From the Valve Academic Research Consortium
Martin B. Leon, Nicolo Piazza, Eugenia Nikolsky, Eugene H. Blackstone, Donald E. Cutlip,
Arie Pieter Kappetein, Mitchell W. Krucoff, Michael Mack, Roxana Mehran, Craig Miller,
Marie-angéle Morel, John Petersen, Jeffrey J. Popma, Johanna J. M. Takkenberg, Alec Vahanian,
Gerrit-Anne van Es, Pascal Vranckx, John G. Webb, Stephan Windecker, Patrick W. Serruys
New York, New York
Objectives To propose standardized consensus definitions for important clinical endpoints in transcatheter aortic valve im-
plantation (TAVI), investigations in an effort to improve the quality of clinical research and to enable meaningful
comparisons between clinical trials. To make these consensus definitions accessible to all stakeholders in TAVI
clinical research through a peer reviewed publication, on behalf of the public health.
Background Transcatheter aortic valve implantation may provide a worthwhile less invasive treatment in many patients with se-
vere aortic stenosis and since its introduction to the medical community in 2002, there has been an explosive growth
in procedures. The integration of TAVI into daily clinical practice should be guided by academic activities, which requires a
harmonized and structured process for data collection, interpretation, and reporting during well-conducted clinical trials.
Methods and
Results The Valve Academic Research Consortium established an independent collaboration between Academic Research
organizations and specialty societies (cardiology and cardiac surgery) in the USA and Europe. Two meetings, in San
Francisco, California (September 2009) and in Amsterdam, the Netherlands (December 2009), including key physi-
cian experts, and representatives from the U.S. Food and Drug Administration (FDA) and device manufacturers, were
focused on creating consistent endpoint definitions and consensus recommendations for implementation in TAVI clin-
ical research programs. Important considerations in developing endpoint definitions included: 1) respect for the histor-
ical legacy of surgical valve guidelines; 2) identification of pathophysiological mechanisms associated with clinical
events; 3) emphasis on clinical relevance. Consensus criteria were developed for the following endpoints: mortality,
myocardial infarction, stroke, bleeding, acute kidney injury, vascular complications, and prosthetic valve performance.
Composite endpoints for TAVI safety and effectiveness were also recommended.
Conclusions Although consensus criteria will invariably include certain arbitrary features, an organized multidisciplinary
process to develop specific definitions for TAVI clinical research should provide consistency across studies
that can facilitate the evaluation of this new important catheter-based therapy. The broadly based consen-
sus endpoint definitions described in this document may be useful for regulatory and clinical trial
purposes. (J Am Coll Cardiol 2011;57:253–69) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.12.005(
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Tince the introduction of transcatheter aortic valve implan-
ation (TAVI) in 2002 (1), there has been increasing
nterest in the field of catheter-based treatment of high-
urgical-risk patients with symptomatic aortic stenosis (AS)
rom the Columbia University Medical Center, Center for Interventional Vascular
herapy, New York, New York. The Valve Academic Research Consortium (VARC)
onsists of representatives from several independent Academic Research Organizations,
everal Surgery and Cardiology Societies, members of the U.S. Food and Drug
dministration, and several independent experts (Appendices 1 and 2). Grants were
rovided to the ARC Board including representatives of The Cardiovascular Research
oundation, Cardialysis, Duke Clinical Research Institute and Harvard Clinical Research
nstitute to cover the costs of travel, meeting rooms, and lodging for academic attendees
t the San Francisco and Amsterdam meetings by Edwards Lifesciences and Medtronic a2–7). Introduction of this new technology should ideally
ollow the standard bench-to-bedside evidence-based med-
cine pattern, starting with pre-clinical testing and advanc-
ng to clinical investigations. Unfortunately, the explosive
orporation. All funds not utilized for the aforementioned travel-related purposes have
een returned to the sponsors. Funding was provided by Cardialysis BV on behalf of the
alve Academic Research Consortium. The VARC meetings involved members of the
nterventional Cardiology Devices Branch, of the Office of Device Evaluation, Center for
evices and Radiological Health, USFDA. The opinions or assertions herein are the
rivate views of the authors and are not to be construed as reflecting the views of the FDA.
his article is copublished in the European Heart Journal.
Manuscript received July 8, 2010; revised manuscript received September 30, 2010,
ccepted October 6, 2010.
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VARC Consensus Endpoints After TAVI for High-Risk AS January 18, 2011:253–69rowth of TAVI (Fig. 1) has created a ‘clinical data
onundrum’: investigators were not prepared to optimally
rganize and interpret clinical data for this radically different
reatment, rendering thoughtful assessment of clinical trial
utcomes difficult and inter-study results comparisons prob-
ematic (8–11).
Surgical valve clinical research guidelines have been
eveloped using a more traditional ‘multi-society approach,’
ave been revised approximately every 10 years, incorporate
ot merely clinical endpoints but also issues such as struc-
ural valve deterioration and non-structural valve dysfunc-
ion, and often divide clinical events into those that are valve
nd non-valve related (12). Interventional cardiology has a
radition of agreed upon clinical endpoint definitions and
linical trial methodologies (13,14) and recently has incor-
orated a consensus process to standardize key endpoint
efinitions by convening an Academic Research Consor-
ium (ARC) among Academic Research Organizations
AROs) from the USA and Europe joined by representa-
ives from the USFDA and device manufacturers (14). The
RC process demonstrated the power of a well-managed
nternational goal-directed academic consortium collaborat-
ng effectively with the FDA and industry to establish
onsensus clinical endpoint definitions and to improve the
onduct of clinical research.
In the spirit of the ARC-mission statement (14), the
Valve Academic Research Consortium’ (VARC) was orga-
ized as an amalgam of the ARO and multi-society guide-
ine models with strong participation from independent
xperts, the FDA, and medical device manufacturers (Ap-
Figure 1 Current Generation Transcatheter Aortic Valve Therap
(A) balloon-expandable, stainless steel support structure, bovine pericardial valve;endices 1 and 2). Two in-person meetings on September9, 2009, in San Francisco, CA, and on December 5 to 6,
009, in Amsterdam, the Netherlands, involving VARC
tudy group members and invited guests (including the
DA and industry representatives) provided much of the
ubstantive discussion from which this consensus manu-
cript was derived.
The goals of VARC are to combine the expertise of
urgeons, interventionalists, medical cardiologists, clinical
rialists, and other specialists (representing relevant disci-
lines including echocardiography, vascular medicine, and
eurology) to arrive at a consensus for: 1) selecting appropri-
te clinical endpoints reflecting device, procedure and
atient-related effectiveness and safety, and 2) standardizing
efinitions for single and composite clinical endpoints.
Importantly, this first consensus manuscript was not
ntended as a ‘guidelines statement’ or a ‘guidance docu-
ent,’ but rather should be viewed as a roadmap to facilitate
he standardization of future TAVI and other aortic valve
linical research.
rinciples for Selecting and Defining Clinical
ndpoints for Transcatheter Aortic Valve
mplantation Investigations:
eneral Considerations
riteria for endpoint definitions. The definitions of ma-
or clinical endpoints must follow a multi-step thought
rocess.
• Each major endpoint should address issues that estab-
lish either the safety and/or the effectiveness of the
elf-expanding, nitinol support structure, porcine pericardial valve.ies
(B) sproposed new therapy.
I
r
r
e
D
d
t
p
w
e
m
d
a
a
b
t
v
c
d
i
p
d
y
s
l
P
M
b
s
i
b
a
h
d
e
V
c
o
a
‘
o
s
u
p
r
p
s
u
m
e
p
i
o
p
M
A
i
g
t
r
(
h
u
i
c
‘
i
c
t
m
C
a
a
d
s
c
C
255JACC Vol. 57, No. 3, 2011 Leon et al.
January 18, 2011:253–69 VARC Consensus Endpoints After TAVI for High-Risk ASX Safety is characterized by the avoidance of device-
related or procedural complications.
X Effectiveness is a more complex descriptor, as it
encompasses both the avoidance of negative
disease-related outcomes and objective measures of
clinical functional benefit.
• The endpoints should relate short- and long-term
pathophysiological mechanisms to meaningful clinical
events.
• Endpoint definitions must be consistent with the body
of published literature, but still reflect unique or
evolving aspects of the new therapy.
• The emphasis should be on definitions that accurately
represent essential patient-oriented clinical outcomes.
• The endpoints must be well defined (preferably
through blinded adjudication processes) such that they
can be to be subjected to statistical analysis.
t is helpful to reference a standardized definition format
egarding: 1) the specific treatment; 2) the place of occur-
ence; 3) the time of occurrence; and 4) the specific type of
ndpoint.
evice, procedure, and patient-oriented outcomes. En-
point definitions for TAVI will in most cases be charac-
erized in relation to the specific implant device, the implant
rocedure, and the resultant patient-oriented outcomes,
hich can occur at any time after the procedure. During the
arly phases of therapy development, particular attention
ust be directed to the safety and performance of the
evice. Therefore, VARC tries to strike a compromise by
lso elucidating device and procedure-related events, which
re essential to the understanding of a new class of catheter-
ased therapies.
Since TAVI is fundamentally the placement of a pros-
hetic aortic valve and will be compared with surgical aortic
alve replacement (AVR), tradition should be respected and
rucial endpoints such as all-cause mortality and device
urability must be assessed longitudinally for the life of the
mplant (12). However, primary clinical endpoints used in
ivotal clinical trials for regulatory approval of TAVI
evices should incorporate a shorter time domain of 1 to 2
ears after the index procedure. These recommended
horter time horizons should not discourage the standard
ong-term follow-up procedures for prosthetic heart valves.
roposed Safety and Efficacy Endpoints
ortality. All-cause mortality in surgical clinical trials has
ecome the ‘gold standard’ in previously published consen-
us and guideline documents (12). The advantage of report-
ng all-cause mortality is that it is both objective (without
ias) and pragmatic from the standpoint of ascertainment
nd adjudication. However, the use of all-cause mortality in
igh-risk TAVI patients may be misleading, resulting in
isproportionate reporting of mortal events unrelated to
ither the treatment device or the procedure. Therefore, mARC proposes to use all-cause mortality as a primary
linical endpoint, but also recommends further subdivision
f mortality, specifically denoting cardiovascular mortality as
n important secondary endpoint (Table 1). Of note,
unknown’ deaths should be considered as cardiovascular in
rigin and to improve the ascertainment of death, the social
ecurity death index or national death registries should be
tilized in cases of patients lost to follow-up.
Consistent with surgical guidelines and surgical clinical trial
ractices (12), mortality should be formally assessed and
eported at 30 days after the index procedure (or longer if the
atient was not discharged from the treatment hospital or a
econdary convalescent facility). Since there may be either
nknown or under-reporting of early device failure modes, a
ore appropriate duration for all-cause mortality as a primary
ndpoint in TAVI clinical trials is 1 year after the index
rocedure. After 1 year, mortality should be recorded at yearly
ntervals for a minimum of 5 years, or ideally, for the duration
f the prosthetic valve implant, in the form of well-defined
ost-approval surveillance registries.
yocardial infarction. In 2007, the joint ESC/ACC/
HA/WHF task force for the redefinition of Myocardial
nfarction (MI) established diagnostic criteria and updated
uidelines for a universal MI definition to be used in clinical
rials (13). This universal MI definition is highly sensitive,
elying heavily on the measurement of cardiac biomarkers
preferably troponin). Conversely, surgical valve guidelines
ave adopted a ‘minimalist’ approach to MI definitions,
sually ignoring biomarker diagnoses and excluding both
ntra-operative and post-operative MIs, unless the MI was
aused by a coronary embolus (12).
Valve Academic Research Consortium proposes a more
centrist’ approach to MI definitions after TAVI, recogniz-
ng that many patients have coexistent aortic valve and
oronary artery disease (15), which requires an MI defini-
ion that does not exclude peri-procedural or late MIs that
ay impact patient outcomes. Valve Academic Research
onsortium proposes to define peri-procedural MI as an
cute ischaemic event that is associated with documented
nd clinically significant myocardial necrosis (Table 2). This
efinition does not include ischaemic events after TAVI or
urgery defined solely by biomarker elevations without a
linically evident ischaemic insult. Since troponin measure-
ardiovascular MortalityTable 1 Cardiovascular Mortality
Any one of the following criteria:
Any death due to proximate cardiac cause (e.g., myocardial infarction, cardiac
tamponade, worsening heart failure)
Unwitnessed death and death of unknown cause
All procedure-related deaths, including those related to a complication of the
procedure or treatment for a complication of the procedure
Death caused by noncoronary vascular conditions such as cerebrovascular
disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm,
or other vascular diseaseents are an extremely sensitive biomarker of myocardial
n
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VARC Consensus Endpoints After TAVI for High-Risk AS January 18, 2011:253–69ecrosis, VARC recommends that CPK-MB should be the
eri-procedural biomarker of choice in TAVI clinical trials.
iomarker samples ideally should be obtained at baseline,
wice after the procedure (separated by at least 6 h), and if
till elevated, daily thereafter until values are declining.
ince TAVI may involve open surgical procedures (e.g.,
ransapical access), the biomarker diagnosis of peri-
rocedural MI requires a 20% increase in the second
ost-procedure sample and a threshold elevation of ten
imes the upper normal range. An electrocardiogram should
e collected at baseline and at least once after the procedure
rior to discharge to document the presence or absence of
ew Q-waves. The peri-procedural interval is inclusive of all
vents that begin within 72 h of the index procedure. Acute
schemic events occurring after 72 h are considered sponta-
eous MIs and are defined in accordance with the universal
I guidelines (13), as further modified by ARC (14) (Table
). Finally, a confirmed coronary embolus, occurring at any
ime, should be reported as an independent event, if biomarker
hanges and associated findings fulfill definition criteria.
troke. Recently, two reports have indicated a high fre-
uency of new perfusion abnormalities (presumably em-
olic) detected by diffusion-weighted magnetic resonance
maging (MRI) studies soon after TAVI (16,17), although
he clinical significance of these early perfusion defects
emains unclear. Strokes during and after TAVI may occur
ue to embolic events from multiple sources, procedure-
yocardial InfarctionTable 2 Myocardial Infarction
Peri-procedural MI (72 h after the index procedure)
New ischemic symptoms (e.g., chest pain or shortness of breath), or new
ischemic signs (e.g. ventricular arrhythmias, new or worsening heart
failure, new ST-segment changes, hemodynamic instability, or imaging
evidence of new loss of viable myocardium or new wall motion
abnormality), AND
Elevated cardiac biomarkers (preferably CK-MB) within 72 h after the index
procedure, consisting of two or more post-procedure samples that are
0.6 to 8 h apart with a 20% increase in the second sample and a
peak value exceeding 10 the 99th percentile URL, or a peak value
exceeding 5 the 99th percentile URL with new pathological Q waves
in at least 2 contiguous leads.
Spontaneous MI (72 h after the index procedure)
Any one of the following criteria:
Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with
at least one value above the 99th percentile URL, together with
evidence of myocardial ischemia with at least one of the following:
ECG changes indicative of new ischemia [new ST-T changes or new LBBB]
New pathological Q waves in at least two contiguous leads
Imaging evidence of new loss of viable myocardium or new wall motion
abnormality
Sudden, unexpected cardiac death, involving cardiac arrest, often with
symptoms suggestive of myocardial ischemia, and accompanied by
presumably new ST-segment elevation, or new LBBB, and/or evidence
of fresh thrombus by coronary angiography and/ or at autopsy, but
death occurring before blood samples could be obtained, or at a time
before the appearance of cardiac biomarkers in the blood.
Pathological findings of an acute myocardial infarction.
K  creatine kinase; ECG  electrocardiographic; LBBB  left bundle branch block; MI 
yocardial infarction; URL  upper reference limit.elated aortic dissections, ischemia from hypotension, or
bemorrhagic complications associated with adjunctive phar-
acotherapy. Insights on stroke definitions are in a state of
volution and VARC examined viewpoints derived from
everal sources, including recent multi-society consensus
ocuments (12,18,19) and multi-center randomized trials,
n which stroke was an important endpoint (20–29). Valve
cademic Research Consortium considered 5 important
ssues in arriving at clinically relevant stroke definitions, as
ollows: 1) a clinical diagnosis of stroke which ruled out
etabolic or toxic encephalopathy, pharmacological influ-
nces, and non-central neurological symptoms; 2) the role
f neuroimaging studies for confirmation of the diagnosis;
) the distinction of stroke vs. transient ischaemic attack
TIA) (including timing); 4) categorization of stroke into
ajor and minor events based on the degree of disability as
efined by conventional neurological assessment tools; and
) subclassification of strokes into hemorrhagic, ischaemic,
nd undetermined categories.
Table 3 outlines the diagnostic criteria and specific
efinitions for TIA and stroke as proposed by VARC.
here is growing acceptance that neuroimaging is an
mportant biomarker for the diagnosis of neuronal injury
nd stroke (18,19) and diffusion-weighted MRI is generally
onsidered the procedure of choice in the context of acute
eurological syndromes (30). If a stroke is reported without
vidence of confirmation of the diagnosis by the methods
trokeTable 3 Stroke
Stroke diagnostic criteria
Rapid onset of a focal or global neurological deficit with at least one of the
following: change in level of consciousness, hemiplegia, hemiparesis,
numbness or sensory loss affecting one side of the body, dysphasia or
aphasia, hemianopia, amaurosis fugax, or other neurological signs or
symptoms consistent with stroke
Duration of a focal or global neurological deficit 24 h; OR 24 h, if
therapeutic intervention(s) were performed (e.g. thrombolytic therapy or
intracranial angioplasty); OR available neuroimaging documents a new
hemorrhage or infarct; OR the neurological deficit results in death
No other readily identifiable nonstroke cause for the clinical presentation (e.g.,
brain tumor, trauma, infection, hypoglycemia, peripheral lesion,
pharmacological influences)*
Confirmation of the diagnosis by at least one of the following:
Neurology or neurosurgical specialist
Neuroimaging procedure (MR or CT scan or cerebral angiography)
Lumbar puncture (i.e., spinal fluid analysis diagnostic of intracranial
hemorrhage)
Stroke definitions
Transient ischemic attack:
New focal neurological deficit with rapid symptom resolution
(usually 1 to 2 h), always within 24 h
Neuroimaging without tissue injury
Stroke: (diagnosis as above, preferably with positive neuroimaging study)
Minor—Modified Rankin score 2 at 30 and 90 days†
Major—Modified Rankin score 2 at 30 and 90 days
Patients with non-focal global encephalopathy will not be reported as a stroke without unequiv-
cal evidence based upon neuroimaging studies. †Modified Rankin score assessments should be
ade by qualified individuals according to a certification process. If there is discordance between
he 30 and 90 day Modified Rankin scores, a final determination of major versus minor stroke will
e adjudicated by the neurology members of the clinical events committee.
CT  computed tomography; MR  magnetic resonance.
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January 18, 2011:253–69 VARC Consensus Endpoints After TAVI for High-Risk ASutlined in Table 3, the event may still be considered a
troke on the basis of the clinical presentation alone, but
ormal adjudication by qualified neurologists who are mem-
ers of, or consultants to, a clinical events committee is
andatory. Patients with a global encephalopathy will not
e reported as a stroke without unequivocal neuroimaging
ndings. Diagnosis of stroke in patients with a previously
ocumented neurological deficit is more problematic and
equires clinical assessment by a neurologist accompanied by
ppropriate new CT or MRI findings. In patients with a
revious stroke and persistent neurological deficits, baseline
re-treatment neurological consultation and neuroimaging
tudies are recommended.
The earliest time of new neurological symptoms is de-
ned as the time of onset of the stroke or TIA. When a
atient awakens or begins responding (if previously uncon-
cious) after the index procedure with obvious new signs of
neurological deficit, the stroke or TIA is considered to
ave occurred during the index procedure. The diagnosis of
transient ischemic attack is defined as complete resolution of
ew neurological symptoms usually within 1 to 2 h but
lways within 24 h and also requires a normal neuroimaging
tudy (18,19). A stroke fulfiling the diagnostic criteria in
able 3 is classified as a major stroke based upon ongoing
ignificant clinical disability, defined as a Modified Rankin
core 2. Although the initial Modified Rankin Score
hould be recorded after 7 days or at the time of hospital
ischarge, the attribution of clinically significant disability
equires a Modified Rankin Score 2 at both 30 and 90
ays follow-up (allowing sufficient time for stroke disability
o stabilize). The Modified Rankin Score determinations
hould be performed by qualified individuals who have
ndergone a certification process (31–34). A minor stroke
ust also fulfill stroke diagnostic criteria, with either reso-
ution of new neurological symptoms within 24 h or
ersistence of symptoms 24 h and a Modified Rankin
core 2 at both 30 and 90 days follow-up. If there is
iscordance between the 30 and 90-day Modified Rankin
cores, the final determination of major vs. minor strokes
hould be adjudicated by the neurology members of the
linical events committee. For the purposes of clinical trial
ndpoints, VARC advocates that only major strokes should
e considered as an important safety endpoint, however, all
eurological events should be reported as adverse events.
Stroke will be further stratified into ischemic, hemor-
hagic, or undetermined origin utilizing newly proposed
efinitions by an FDA consensus panel (35). Ischemic
troke is as an acute symptomatic episode of focal cerebral,
pinal, or retinal dysfunction caused by an infarction of
entral nervous system tissue. Hemorrhagic stroke is an
cute symptomatic episode of focal or global cerebral or
pinal dysfunction caused by a non-traumatic intraparen-
hymal, intraventricular, or subarachnoid hemorrhage. An
ndetermined stroke is a stroke with insufficient informa-
ion to allow categorization as either of ischemic or haem-
rrhagic origin. ileeding complications. Bleeding is a critical safety end-
oint in evaluating contemporary pharmacological agents
nd interventional devices (36–44). Valve Academic Re-
earch Consortium carefully reviewed several literature
ources including: 1) landmark clinical trials assessing the
ffects of anti-thrombotic medications in stable and acute
oronary syndromes (45–59); 2) a report by the Control of
nticoagulation Subcommittee of the International Society
n Thrombosis and Haemostasis (60); and 3) surgery
uidelines after cardiac valve procedures (12).
The definition of clinically meaningful bleeding was
uided by the following principles: 1) the definition must be
ased on objective criteria, including an obvious source of
leeding or number of transfusions; 2) serious or meaningful
leeding must result in death, be life-threatening, be proven
o be associated with increased long-term mortality, cause
hronic sequellae, or consume major health-care resources.
he VARC definition of bleeding complications (Table 4)
s divided into life-threatening or disabling bleeding, major
leeding, and minor bleeding; anything but minor bleeding
onstitutes a serious or meaningful bleeding event.
Given the ample body of literature suggesting that
dministration of whole blood or red blood cell (RBC)
ransfusions in patients with cardiovascular pathology may
e potentially harmful (41–44), VARC considers that any
hole blood or RBC transfusion needs to be reported in the
ase report forms, including the number of transfused units,
egardless of the presence or absence of overt bleeding.
ransfusions also need to be further stratified into those
ssociated with overt bleeding and those in the absence of
vert bleeding. Bleeding complications and transfusions
hould also be characterized relative to the time of occur-
ence including during the procedure, within the index
ospitalization, or post-discharge.
cute kidney injury. The natural history of acute kidney
leedingTable 4 Bleeding
Life-threatening or disabling bleeding
Fatal bleeding OR
Bleeding in a critical area or organ, such as intracranial, intraspinal,
intraocular, or pericardial necessitating pericardiocentesis, or intramuscular
with compartment syndrome OR
Bleeding causing hypovolemic shock or severe hypotension requiring
vasopressors or surgery OR
Overt source of bleeding with drop in hemoglobin of 5 g/dl or whole blood or
packed red blood cells (RBCs) transfusion 4 U*
Major bleeding
Overt bleeding either associated with a drop in the hemoglobin level of at
least 3.0 g/dl or requiring transfusion of two or three units of whole blood/
RBC AND
Does not meet criteria of life-threatening or disabling bleeding
Minor bleeding
Any bleeding worthy of clinical mention (e.g., access site hematoma) that does
not qualify as life-threatening, disabling or major
Given 1 U of packed RBC typically will raise blood hemoglobin concentration by 1 g/dl, an
stimated decrease in hemoglobin will be calculated.njury (AKI) in a variety of clinical settings (61–70) is now
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VARC Consensus Endpoints After TAVI for High-Risk AS January 18, 2011:253–69ell understood, including the recognition that even small
ecreases in kidney function can have a dramatic impact on
he risk for subsequent mortality (69,70). In recent reports,
KI has been observed in 12% to 28% of patients under-
oing TAVI and was associated with a four times higher
ost-procedural mortality (71,72).
In defining the stages of AKI, VARC proposes adopting
erum creatinine criteria from the ‘modified’ RIFLE (Risk,
njury, Failure, Loss, and End-stage kidney disease) classi-
cation (Table 5) (73). The RIFLE classification (74–76)
as been validated in the setting of intensive care units and
ardiac surgery (77–81) and provides practical definitions
or early stages of renal dysfunction when kidney injury can
till be prevented, as well as stages when the kidney has
lready been damaged and renal failure is established.
odifications of the original RIFLE classification include
wo important changes: 1) smaller changes in serum creat-
nine (0.3 mg/dl) are included in stage 1 (‘Risk’) (82); 2) the
Loss’ and ‘End-stage kidney disease’ categories have been
emoved due to a lack of uniform indications and timing of
enal replacement therapy (RRT) and variability in RRT
esources in different countries. An outer bound of 72 h
rom the index procedure for diagnosing AKI was selected
ased on evidence that adverse outcomes were observed
hen the elevation occurred within 24 to 48 h of the
rocedure (83) and to ensure that the process was both acute
nd related to the procedure itself rather than as a conse-
uence of post-procedure multi-organ system failure. Risk,
njury, Failure, Loss, and End-stage kidney disease classi-
cations also stress the predictive value of urine output
riteria in defining AKI, but VARC has not included this
easure in the definition of AKI since urine outputs may
ot be measured accurately or routinely in all cases.
Valve Academic Research Consortium proposes to utilize
he modified RIFLE classification to: 1) capture even the
arliest stages of AKI (stage 1) on case report forms; 2) define
KI as either stage 2 or 3; and 3) report any case of RRT
haemodialysis, peritoneal dialysis, or haemofiltration) occur-
ing during the index hospitalization or within 30 days after the
ndex procedure. Given the well-recognized damaging impact
f contrast media on renal function, VARC also recommends
o report the volume and type of contrast medium used during
cute Kidney Injury (Modified RIFLE Classification)Table 5 Acute Kidney Injury (Modified RIFLE Classification)
Change in serum creatinine (up to 72 h) compared with baseline
Stage 1 Increase in serum creatinine to 150% to 200% (1.5 to 2.0  increase
compared with baseline) or increase of 0.3 mg/dl (26.4 mmol/l)
Stage 2 Increase in serum creatinine to 200% to 300% (2.0 to 3.0  increase
compared with baseline) or increase between 0.3 mg/dl (26.4 mmol/l)
and 4.0 mg/dl (354 mmol/l)
Stage 3* Increase in serum creatinine to 300% (3  increase compared with
baseline) or serum creatinine of 4.0 mg/dl (354 mmol/l) with an acute
increase of at least 0.5 mg/dl (44 mmol/l)
Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective
f other criteria.he index procedure.ascular complications. Recent TAVI literature indicates
hat major vascular complications using various non-
tandardized definitions (e.g., with or without including the
eed for blood transfusions) occur at a frequency of 4% to
4% and are associated with a two- or three-fold higher
0-day mortality (84–87). In defining vascular complica-
ions, VARC referenced the reporting standards of the
ociety of Vascular Surgery for defining and reporting
ascular complications following endovascular aortic graft
epair procedures (88).
Valve Academic Research Consortium proposes to report
oth major and minor vascular complications, but to only
onsider major vascular complications as an important
linical endpoint. Of note, the ‘access site’ is defined as any
ocation (arterial or venous) traversed by a guide-wire, a
atheter or a sheath [including the left ventricular (LV) apex
nd the aorta] and ‘access related’ is defined as any adverse
linical consequence possibly associated with any of the
ccess sites used during the procedure. The VARC defini-
ions for major and minor vascular complications are de-
cribed in Table 6.
Many vascular situations require special notice. Femoral
ascular access and closure in many centers is routinely
chieved using surgical cut-down procedures, and therefore,
re-planned surgical access and/or closure should be con-
idered as part of the procedure and not as a complication.
imilarly, uncomplicated non-femoral (e.g., retroperitoneal,
liac, subclavian, or aortic) surgical access for sheath entry
planned or unplanned) is not considered a vascular com-
lication, unless untoward clinical consequences are docu-
ented (e.g., bleeding complications). However, interven-
ional or surgical repair for failed percutaneous closure of the
rteriotomy site during the index procedure without other
linical sequellae (Table 6) is considered a minor vascular
ascular Access Sitend Access-Related ComplicationsTable 6 Vascular Access Siteand Access-Related Complications
Major vascular complications
Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis, perforation,
rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible
nerve injury, or compartment syndrome) leading to either death, need for
significant blood transfusions (4 U), unplanned percutaneous or surgical
intervention, or irreversible end-organ damage (e.g., hypogastric artery
occlusion causing visceral ischemia or spinal artery injury causing
neurological impairment)
Distal embolization (noncerebral) from a vascular source requiring surgery or
resulting in amputation or irreversible end-organ damage
Minor vascular complications
Access site or access-related vascular injury (dissection, stenosis, perforation,
rupture, arteriovenous fistula or pseudoaneuysms requiring compression or
thrombin injection therapy, or hematomas requiring transfusion of 2 but,
4 U) not requiring unplanned percutaneous or surgical intervention and not
resulting in irreversible end-organ damage
Distal embolization treated with embolectomy and/or thrombectomy and not
resulting in amputation or irreversible end-organ damage
Failure of percutaneous access site closure resulting in interventional (e.g.,
stent-graft) or surgical correction and not associated with death, need for
significant blood transfusions (4 U), or irreversible end-organ damage
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January 18, 2011:253–69 VARC Consensus Endpoints After TAVI for High-Risk ASomplication. Considering the recent proliferation of vas-
ular access approaches and the recognition that specific
ccess sites and techniques may be associated with either
ncreased or decreased complications, VARC strongly rec-
mmends that detailed information is recorded on the
ccess site and technique for each procedure.
A special circumstance relates to complications associated
ith the left-ventricular apex site during transapical TAVI
rocedures. Although such complications are less frequent
han transarterial vascular complications, a recent report
ndicates that the clinical consequences (including death)
an be more serious (89). Major complications associated
ith transapical TAVI procedures include bleeding, pseu-
oaneurysm formation (with or without rupture), and hae-
odynamic instability requiring urgent transarterial cardio-
ulmonary bypass support. Valve Academic Research
onsortium proposes that all such complications associated
ith transapical TAVI be reported in case report forms and
hat clinical consequences resulting from such complications
otential Failure Modesf Prosthetic Valve DysfunctionTable 7 Potential Failure Modesof Prosthetic Valve Dysfunction
Aortic stenosis
Stent creep
Pannus
Calcification
Support structure deformation (out-of-round configuration), under-expansion,
fracture, or trauma (cardio-pulmonary resuscitation, blunt chest trauma)
Mal-sizing (prosthesis-patient mismatch)
Endocarditis
Prosthetic valve thrombosis
Native leaflet prolapse impeding prosthetic leaflet motion
Aortic regurgitation
Pannus
Calcification
Support structure deformation (out-of-round configuration), recoil,
under-expansion, fracture, insufficient radial strength, or trauma
(cardiopulmonary resuscitation, blunt chest trauma)
Endocarditis
Prosthetic valve thrombosis
Malposition (too high, too low)
Acute mal-coaptation
Leaflet wear, tear/perforation, prolapse, or retraction
Suture breakage or disruption
Native leaflet prolapse impeding prosthetic leaflet motion
Prosthetic Aortic Valve Stenosis Criteria*Table 8 Prosthetic Aortic Valve Stenosis Cr
Parameter Normal
Peak velocity (m/s)† 3
Mean gradient (mm Hg)† 20
Doppler velocity index 0.30
Effective orifice area (cm2) 1.2
Contour of the jet velocity through
the prosthetic valve
Triangular, early peaki
Acceleration time (ms) 80*In conditions of normal or near normal stroke volume (50–70 ml). †These
regurgitation.e registered under the appropriate clinical endpoints (e.g.,
leeding, stroke, mortality).
rosthetic Valve Performance
he clinical presentation of patients with prosthetic valve
ysfunction is usually consistent with symptoms and signs
f either valvular regurgitation or stenosis. Valve Academic
esearch Consortium proposes only two criteria to evaluate
mpaired prosthetic valve performance: 1) prosthetic valve
aemodynamics assessed by echocardiography and 2) asso-
iated clinical findings indicating impaired cardiovascular or
alvular function (e.g., new or worsening congestive heart
ailure). Transthoracic echocardiography (TTE) is usually
dequate to evaluate prosthetic aortic valve function (90),
lthough transoesophageal echocardiography (TEE) may be
ery useful in the setting of technically challenging or
omplex cases. Serial echocardiography evaluations after
urgical AVR and TAVI should be performed at baseline,
oon after the index procedure (ideally within 24 to 48 h,
ut always before discharge), at 1 month (especially for
AVI), 12 months, and yearly thereafter (91,92). This
ollow-up schedule is more intensive than recommended in
he AHA/ACC and ESC guidelines for follow-up after
urgical AVR (91,92), but more frequent documentation of
alve function and position is considered desirable for TAVI
linical trials.
Although the VARC definitions for impaired prosthetic
alve performance discount mechanistic characterizations,
alve failure mode(s) should be recorded whenever possible
n case report forms (Table 7). In addition to echocardiog-
aphy, multi-slice computed tomography may also provide
seful insights into the responsible patho-biological mech-
nisms of device malfunction (93,94).
rosthetic aortic stenosis and regurgitation. Utilizing the
ecent prosthetic valve echocardiography guidelines (90),
he severity of prosthetic aortic valve stenosis is graded as: 1)
ormal; 2) possible; or 3) significant (Table 8) and pros-
hetic aortic valve regurgitation (central or paravalvular) as:
) mild; 2) moderate; or 3) severe (Table 9). The clinical
ignificance of prosthetic valve dysfunction is further sup-
orted by the presence of clinical signs, symptoms, and/or
vents (e.g., re-hospitalization for worsening symptoms,
e-operation or death).
*
Possible Stenosis Significant Stenosis
3–4 0.4
20–35 0.35
0.29–0.25 0.25
1.2–0.8 0.80
riangular to intermediate Rounded, symmetrical contour
80–100 100iteria
ng Tparameters are more affected by flow, including concomitant aortic
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VARC Consensus Endpoints After TAVI for High-Risk AS January 18, 2011:253–69Transcatheter aortic valve implantation devices are asso-
iated with a higher frequency of mild and moderate
aravalvular aortic regurgitation (AR) than surgical AVR
95–107). There is a need to develop improved definitions
nd to better understand the long-term clinical implications
f paravalvular prosthetic AR. Unfortunately, the precise
rading of paravalvular AR remains controversial and many
chocardiography experts believe that grading schemes for
rosthetic central and paravalvular AR should be different
90,108–111). Recently, in the setting of TAVI, criteria for
ssessing paravalvular AR severity have emphasized a ‘jet
natomy’ classification, stressing the location, circumferen-
ial extent, and width of the AR jet (90). Hemodynamic
actors can also be useful to assess the AR severity imme-
iately after valve implantation (e.g., loss of aortic dicrotic
otch, equalization of end-diastolic aortic and left ventric-
lar pressures). Since there is lack of clarity concerning the
ong-term clinical implications of mild and moderate para-
alvular AR after TAVI, echocardiography core laboratories
re useful to ensure consistent evaluation methods. Echo-
ardiograms should be performed annually in those patients
nown to have post-procedural paravalvular AR.
rosthetic aortic valve thrombosis and endocarditis.
lthough prosthetic valve thrombosis and prosthetic valve
ndocarditis have been included as potential failure modes
or prosthetic valve dysfunction (Table 7), they require
eporting as individual endpoints. Valve thrombosis is any
hrombus attached to or near an implanted valve that
ccludes part of the blood flow path, interferes with valve
unction, or is sufficiently large to warrant treatment (12).
urthermore, valve thrombus found at autopsy in a patient
hose cause of death was not valve related or found at
peration for an unrelated indication should also be re-
orted as valve thrombosis. The diagnosis of prosthetic
alve thrombosis is best discerned during an echocardio-
rosthetic Aortic Valve Regurgitation Criteria (Central and ParavalTable 9 Prosthetic Aortic Valve Regurgitation Criteria (Central
Parameter Mild
Valve structure and motion
Mechanical or bioprosthetic Usually normal
Structural parameters
Left ventricular size Normal
Doppler parameters (qualitative or semiquantitative)
Jet width in central jets (% LVO diameter): color* Narrow (25%)
Jet density: CW Doppler Incomplete or fain
Jet deceleration rate (PHT, ms): CW Doppler† Slow (500)
LV outflow vs. pulmonary flow: PW Doppler Slightly increased
Diastolic flow reversal in the descending aorta
PW Doppler Absent or brief ea
Circumferential extent of paraprosthetic AR (%)‡ 10
Doppler parameters (quantitative)
Regurgitant volume (ml/beat) 30
Regurgitant fraction (%) 30
Parameter applicable to central jets and is less accurate in eccentric jets. †Influenced by left ve
AR  aortic regurgitation; CW  continuous wave; LVO  left ventricular outflow; PW  pulsedraphical examination or during surgical exploration. There pave already been case reports and anecdotes (112) of
ranscatheter prosthetic valve thrombosis with and without
mportant clinical consequences.
The diagnosis of prosthetic valve endocarditis is based on
ne of the following criteria (12):
• reoperation with evidence of abscess, paravalvular leak,
pus, or vegetation confirmed as secondary to infection
by histological or bacteriological studies;
• autopsy findings of abscess, pus, or vegetation involv-
ing a repaired or replaced valve;
• in the absence of reoperation or autopsy, fulfilling the
Duke Criteria for endocarditis (113).
solated case reports of transcatheter aortic valve endocar-
itis have already been published (114,115). Owing to the
ariability in transcatheter valve designs and positioning
ithin the aortic root, meticulous reporting of the pattern of
ndocarditis is mandatory (116).
rosthetic Valve ‘Associated’ Complications
epending on the design characteristics and final implant
osition, prosthetic aortic valves may come in close contact
ith the anterior mitral valve leaflet, the intervalvular
brosa, the aortic annulus, the ventricular septum, the aortic
inuses and root, the coronary arteries, and the cardiac
onduction system. Collectively, these anatomic structures,
hich are contiguous with the prosthetic aortic valve, are
eferred to as the aortic valvar complex (Fig. 2). As such,
rosthetic aortic valve procedures, and in particular TAVI,
ay have untoward effects on any of these structures which
ay result in important clinical consequences. Therefore,
ARC proposes to group these complications as a separate
ndpoint category. However, it must be noted, that some of
hese adverse events may not be directly related to the valve
Paravalvular)
Moderate Severe
Usually abnormal Usually abnormal
Normal/mildly dilated Dilated
Intermediate (26%–64%) Large (65%)
Dense Dense
Variable (200–500) Steep (200)
Intermediate Greatly increased
stolic Intermediate Prominent, holodiastolic
10–20 20
30–59 60
30–50 50
r compliance. ‡For paravalvular aortic regurgitation.vular)and
t
rly diarosthesis itself, but may occur before or after valve implan-
t
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January 18, 2011:253–69 VARC Consensus Endpoints After TAVI for High-Risk ASation (e.g., conduction disturbances after pre-implant bal-
oon aortic valvuloplasty).
onduction disturbances and cardiac arrhythmias. The
lose anatomical relationship between the aortic valvar
omplex and the branching atrioventricular bundle explains
he possible development of conduction abnormalities fol-
owing prosthetic aortic valve procedures (117,118). Follow-
ng surgical AVR, new-onset bundle branch block has been
eported in 16% to 32% of patients and the need for
ermanent pacemakers in 3% to 8% of patients (119–123).
n early experiences with TAVI, new-onset bundle branch
lock has occurred in up to 45% of patients and the need for
ermanent pacemakers has varied from as low as 4% to as
igh as 33% (95–98,124–128). Differences among devices
nd heterogeneity in physician and country-based health-
are thresholds may explain the significant inter-hospital
ariability in new permanent pacemaker requirements after
AVI.
Although the implications of persistent left bundle
ranch block (LBBB) after TAVI are currently unknown,
he presence of new bundle branch block after surgical AVR
as been associated with increased risk of subsequent
rrhythmic events during follow-up (specifically, syncope,
V dissociation, and sudden death) (119,120). Owing to
his association between conduction system abnormalities
nd adverse patient outcomes following surgical AVR and
everal anecdotal reports after TAVI of either early post-
ischarge severe bradyarrhythmic events or sudden cardiac
eath (15), VARC recommends to carefully document the
ccurrence of new conduction system abnormalities (left
undle branch block and third degree atrioventricular
lock), as well as the requirements and indications for new
ermanent pacemakers within 30 days after the procedure.
he timing (days) and location (intra-procedural, in-
Figure 2
The Aortic Valvular Complex, Including the Aortic
Valve, Annulus, Sinuses, Aorta, Coronary Arteries,
Membranous Septum, and the Mitral Valveospital, or post-discharge) of the event should also be Oecorded. To accurately capture such events, daily ECGs
nd continuous telemetry ECG monitoring should be
onsidered while the patients are in-hospital, and should be
equired in patients with any evidence of new conduction
bnormalities or arrhythmias.
Although conduction abnormalities associated with
AVI have been a recent concern, it bears noting that new
nset atrial fibrillation and ventricular arrhythmias have also
een observed after both TAVI and surgical AVR proce-
ures (128). In particular, new onset atrial fibrillation occurs
n as many as 20% to 30% of patients after conventional
urgical AVR (129,130) and any valid comparison of trans-
atheter vs. surgical aortic valve treatment strategies should
nclude a careful analysis of post-therapy supra-ventricular
nd ventricular arrhythmias.
oronary obstruction. Mechanical coronary artery ob-
truction following TAVI or surgical AVR is rare and
ccurs in 1% of patients (96,97). The obstruction typically
ccurs during the index procedure. Importantly, clinical
igns and symptoms may be subtle and not appreciated until
fter the procedure. Possible mechanisms for mechanical
oronary obstruction include: 1) impingement of the coro-
ary ostia by the valve support structure in the setting of
uboptimal valve positioning and/or ‘small aortic root’ anat-
my; 2) embolization from calcium, thrombus, air, or
ndocarditis displacement of native aortic valve leaflets
owards the coronary ostia during TAVI (131,132); and
) suture-related kinking or obstruction or cannulation-
elated obstruction of the coronary ostia associated with
urgical AVR.
The diagnosis of TAVI-associated coronary obstruction
an be determined by imaging studies (coronary angiogra-
hy, intravascular ultrasound, multi-slice CT angiography,
r echocardiography), surgical exploration, or autopsy find-
ngs. Cardiac biomarker elevations and ECG changes indi-
ating new ischaemia provide corroborative evidence.
ther prosthesis-related adverse events. The short- and
ong-term consequences of contact, trauma, or impinge-
ent on the anterior mitral valve leaflet by the ventricular
nd of a transcatheter aortic valve are currently unknown.
evertheless, any new mitral valve dysfunction (e.g., wors-
ning mitral regurgitation or stenosis) or disruption (e.g.,
hordal rupture, leaflet perforation, anterior mitral valve
eaflet aneurysm) related to contact with the transcatheter
alve implant or mitral valve endocarditis (114–116) should
e carefully documented. Other infrequent complications
ollowing TAVI include new ventricular septal defects and
ortic root rupture/perforation/dissection, occurring either
uring the pre-implant balloon aortic valvuloplasty, or
uring the transcatheter valve implant (133,134).
linical Benefit Endpoints
n addition to the avoidance of mortality, specific endpoints
o establish the clinical benefit after TAVI are important.
bjective benefit parameters derived from the heart failure
l
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VARC Consensus Endpoints After TAVI for High-Risk AS January 18, 2011:253–69iterature can be adapted in valve-related clinical trials (135).
everal choices are available, including exercise performance
136), assessment of New York Heart Association (NYHA)
unctional status (137), and various quality of life (138) and
railty questionnaires (139). Each of these symptom evalu-
tion tools has strengths and weaknesses in the TAVI
atient population, which is disproportionately represented
y elderly, frail, individuals with multiple co-morbidities.
or instance, exercise test performance is an appealing
ndpoint, but as aortic valve therapy studies are unblinded,
hey may be biased and they can be difficult to perform in
igh-risk TAVI patients.
Valve Academic Research Consortium has also consid-
red a categorical endpoint of clinical benefit which captures
ailure of current AS therapy; hospitalization for symptoms of
ardiac or valve-related decompensation, at least 30 days after
he index procedure (surgical AVR or TAVI). This end-
oint mandates careful adjudication by a clinical events
ommittee and is defined as hospitalization for symptoms of
alve or cardiac deterioration (e.g. new or worsening heart
ailure, angina, or syncope) requiring either a valve proce-
ure (surgery or interventional treatment) or intensification
f medical management (new or increased use of inotropes,
asopressors, diuretics, and/or vasodilators).
Quality-of-life and healthcare economic instruments can
e useful to assess disability and impairment due to conges-
ive heart failure (e.g., Kansas City Cardiomyopathy Ques-
ionnaire) (140) and for mapping health status compared
ith population-level utility weights (e.g., EuroQOL ques-
ionnaire) (141–143). However, quality-of-life question-
aires are also prone to bias and must be uniformly
dministered. The time points for assessment of the afore-
entioned clinical benefit endpoints should be at 30 days, at
months, and at 1 year after initiating therapy. Valve
cademic Research Consortium recommends that if any
easure of clinical benefit is utilized in clinical trials, there
ust be careful oversight and adjudication by experienced
linical events committees.
The assessment of ‘frailty’ in patients with advanced
alvular heart disease has become increasingly important
nd is usually not included in surgical-risk algorithms.
railty is loosely defined as a biological syndrome of
ecreased reserve and resistance to stressors, resulting from
umulative declines across multiple physiological systems,
nd causing vulnerability to adverse outcomes (139). Vari-
us frailty indices have been developed and have been
orrelated with worsening clinical outcomes in geriatric
atients in intensive care units and after surgery (144–146).
n general, the evaluation of frailty demands a composite
nalysis of several categorical and continuous variables
ncluding mobility, strength, endurance, activities of daily
iving, cognitive impairment, and nutritional status (as
iscerned by body mass index and biomarkers such as serum
lbumin) (147,148). Although there is no standard frailty
ndex which has been applied and validated in high-risk AS
atients, multiple preliminary efforts are ongoing and hARC proposes to include measures of frailty in future
linical trials as a component of clinical benefit endpoints.
herapy-Specific Endpoints
iven the complex nature of TAVI procedures and the
apid evolution of devices and procedural techniques,
ARC proposes to record in case report forms (but not as
ormal endpoints) an open category of therapy-specific
ndpoints which may be relevant to clinical outcomes or
evice performance. Examples of such events include the
ollowing: 1) the unplanned use of cardio-pulmonary bypass
o manage hemodynamic compromise or to reverse proce-
ural complications; 2) conversion from a ‘failed’ percuta-
eous transcatheter procedure to an ‘open’ surgical AVR or
o a surgical-access TAVI (149,150); 3) ventricular perfo-
ation (for any reason) with and without cardiac tamponade
151); 4) prosthetic valve migration or dislocation from the
ative aortic valve landing zone (152,153); 5) frequency,
easons, and results of post-TAVI balloon dilation; 6) fre-
uency, reasons, and results after placement of a second
alve over the original valve, so-called TAVI ‘valve-in-valve’
154,155); 7) integrity of the support structure, including
trut fractures, compression or other evidence of geometry
istortion (requires careful serial imaging modalities includ-
ng cine-fluoroscopic analyses and echocardiography)
90,156–158); 8) instances of device recapture (with or
ithout repositioning), or retrieval (removal from the body)
hich occur during the index procedure; 9) and re-
ntervention (either percutaneous or surgical) for any reason
fter the index procedure (159). As appropriate, the timing
f these events (during the index procedure, in-hospital, or
ost-discharge) should be carefully recorded. This category
s intended to be a dynamic platform and should be added
o the case report forms.
linically Relevant Composite Endpoints
lthough VARC discourages the overuse of composite
ndpoints, to achieve overall impressions of safety and
ffectiveness may require the incorporation of more than single
ndpoints. These strategic assessments of TAVI as an alterna-
ive therapy should ideally include device, procedure, and
atient-oriented factors. Valve Academic Research Consor-
ium proposes three composite endpoints (Table 10): device
uccess (intra-procedure), a combined safety endpoint (at 30
ays), and a combined efficacy endpoint (at 1 year or longer).
Device success is a ‘technical’ composite endpoint meant to
haracterize the acute device and procedural factors which
nderlie vascular access, delivery, and performance of the
AVI system. Echocardiography should be routinely uti-
ized as the standard for measuring prosthetic valve
tenosis and regurgitation immediately after TAVI, and
hould always be performed in a resting state, either
ithin 24 to 48 h after the index procedure or before
ospital discharge.
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January 18, 2011:253–69 VARC Consensus Endpoints After TAVI for High-Risk ASThe 30-day combined safety endpoint is a hierarchical
omposite of the most relevant patient-oriented safety
ndpoints previously defined by VARC (Table 10). In
ddition, a repeat procedure in the first 30 days (either
urgery or intervention) to treat valve-related dysfunction is
lso incorporated in this endpoint. Examples of urgent
epeat procedures would include balloon aortic valvuloplasty
r repeat TAVI (valve-in-valve) to treat either paravalvular
r central severe AR after the TAVI. The focus on 30-day
vents after the index procedure is meant to isolate safety
oncerns largely pertaining to early device performance and
he procedure. Nonetheless, overall patient safety also re-
uires a careful examination of pertinent individual safety
ndpoints over the life history of the device.
The time-sensitive assessment of TAVI effectiveness
equires a more delayed combined efficacy endpoint incorpo-
ating major clinical and valve performance factors. Valve
cademic Research Consortium proposes a 1-year (or
onger) time interval for the combined efficacy endpoint
ntegrating three important endpoints: 1) all-cause mortality
fter 30 days, meant to reflect therapy effectiveness by
easuring prevention of AS-related mortality over time;
) failure of the current therapy for AS, requiring hospital-
zation for symptoms of valve-related or cardiac decompen-
ation (adjudicated episodes of heart failure, angina, or
yncope requiring an aortic valve procedure or intensifica-
ion of medical management); 3) evidence of prosthetic
alve dysfunction, defined using strict echocardiography
riteria, possibly in conjunction with other signs of func-
omposite End PointsTable 10 Composite End Points
Device success
Successful vascular access, delivery and deployment of the device and
successful retrieval of the delivery system
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve (aortic valve area1.2 cm2
and mean aortic valve gradient 20 mm Hg or peak velocity 3 m/s,
without moderate or severe prosthetic valve AR)
Only one valve implanted in the proper anatomical location
Combined safety endpoint (at 30 days)
All-cause mortality
Major stroke
Life-threatening (or disabling) bleeding
Acute kidney injury—Stage 3 (including renal replacement therapy)
Peri-procedural MI
Major vascular complication
Repeat procedure for valve-related dysfunction (surgical or interventional
therapy)
Combined efficacy endpoint (at 1 yr or longer)
All-cause mortality (after 30 days)
Failure of current therapy for AS, requiring hospitalization for symptoms of
valve-related or cardiac decompensation
Prosthetic heart valve dysfunction (aortic valve area 1.2 cm2 and mean
aortic valve gradient 20 mm Hg or peak velocity 3 m/s, OR moderate or
severe prosthetic valve AR)ional deterioration. piscussion
he VARC was convened in response to an urgent call for
tandardized clinical research processes involving the
merging field of transcatheter valve therapies, and more
pecifically, TAVI in high-surgical-risk patients with AS.
he inter-disciplinary nature of TAVI, combining aspects
f both surgical and interventional therapies, presented
pecial challenges and required an enlightened and collab-
rative approach to the development of clinical research
ecommendations and endpoint definitions (160,161). The
ARC initiative is an attempt to achieve a necessary
onsensus among the various subspecialties and stakehold-
rs, such that this innovative treatment strategy may be
valuated objectively and according to a set of practical
ndpoint definitions.
This consensus manuscript is not intended to be inter-
reted as a ‘guidelines’ or ‘guidance’ document and although
horoughly reviewed by individuals from 7 cardiology and
ardiac surgery societies, the content has not been subjected
o a formal society guidelines review process. These stan-
ardized endpoints are measureable, apply to both predicate
urgical and new transcatheter therapies, can be adjudicated
y clinical events committees, and can be used to compare
ndings from different clinical trials. By intent, this consen-
us manuscript was not device-specific and the definitions
an be applied to next generation and iterative TAVI
evices already under early stages of clinical investigation
162–165).
Given the rapid growth in transcatheter valve therapies,
nd the potential exposure of this technology to lower risk
atient populations, it is certain that this preliminary at-
empt to arrive at consensus endpoint definitions for TAVI
ill need refinement in the future. In principle, the consen-
us process calls for the highest standards of clinical re-
earch, including 1) inter-disciplinary experts gathering to
rrive at standardized endpoint definitions, 2) harmonized
nd well-structured data collection, interpretation, and re-
orting for specific TAVI-related clinical events, and 3) the
onsistent use of central core laboratories and independent,
linded endpoint adjudication.
Many of the endpoints discussed in this manuscript are
ufficiently general that they can be applied to other AS
opulations and to other valvular heart disease clinical
esearch scenarios, both surgical and interventional. This is
articularly germane to TAVI clinical research, as new
tudies involving lower risk AS patients are already being
onsidered. Importantly, recent reports and randomized
rials using new catheter-based mitral valve therapies to
reat mitral regurgitation (166–168) also suffer from non-
tandardized endpoint definitions and might well benefit
rom a comparable VARC consensus effort.
This consensus manuscript, which represents the ‘first
tep’ in a much longer road to help improve clinical research
n valvular heart disease, has several limitations. The end-
oint definitions were intended to be reasonably broad, but
n
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VARC Consensus Endpoints After TAVI for High-Risk AS January 18, 2011:253–69onetheless in some instances are also intentionally narrow
o address the specific considerations of TAVI in high-
urgical-risk patients with severe AS. Therefore, application
f all of these endpoint definitions to other patient popu-
ations may be problematic. The important area of pre-
linical device testing, both assessments of valve and support
tructure properties and in vivo animal studies, is beyond the
cope of this manuscript. Other aspects of clinical trial
esign and clinical trial methodologies are also essential to
ptimize clinical research, but similarly, a comprehensive
reatment of these subjects could not be included in this
anuscript. Finally, many global endpoints, such as stroke
nd bleeding and some specific endpoints, such as paraval-
ular regurgitation, are themselves in a state of evolution,
ubject to modifications by other consensus committees in
he near future.
The VARC process embodied in this manuscript was an
mbitious multi-disciplinary attempt to bring order through
onsensus, thereby providing standardization of clinical
esearch in the burgeoning area of transcatheter aortic valve
herapy. Hopefully, this template can also serve as a model
o improve clinical research methodologies in the evaluation
f new therapies for other cardiovascular diseases.
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